secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2026-08-31T20:06:01+00:00
Accession:  0001193125-26-376723
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports 46% ORR in ovarian cancer cohort; NDA submission planned Q1 2027
--------------------------------------------------------------------------------

- ORR of 46% (35/76) in ovarian cancer cohort; median duration of response 10.0 months, median time to response 1.3 months.
- FDA feedback supports NDA for accelerated approval; submission planned Q1 2027.
- Enrollment for primary analysis in platinum-resistant/refractory ovarian cancer completed.
- Safety: mostly Grade 1/2 AEs, 5% discontinuation due to treatment-related AEs.
- Company to present update on all PYNNACLE cohorts at medical conference Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526376723/0001193125-26-376723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312526376723/d441751d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-376723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer